Bert Petersen, MD
Surgical Oncology · New York, NYNPI 1750323267
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,810 of the $6,967 with a category attached, or 83.4%. Gilead accounts for 89.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $6,296 and has fallen 96.2% since, to $242 in 2025.
Across 33 payments — averaging $211.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- AbbVie$411
- Myriad Genetic Laboratories, Inc.$102
- Tactile Systems Technology Inc$85
- Coopersurgical, Inc.$53
- AstraZeneca$43
- plus $62 from 3 others
What the payments were for
- Consulting fees$5,81083%
- Speaking & faculty fees$4006%
- Food & beverage$71410%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 2 | $6,210 |
| AbbVie | 16 | $411 |
| Myriad Genetic Laboratories, Inc. | 4 | $102 |
| Tactile Systems Technology Inc | 4 | $85 |
| Coopersurgical, Inc. | 3 | $53 |
| AstraZeneca | 1 | $43 |
| Elucent Medical | 1 | $25 |
| Sobi, Inc | 1 | $19 |
| Smith+Nephew | 1 | $19 |
How this compares
$6,967 in reported general payments places this provider in the 80th percentile of 173 surgical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 44 | $388 |
| Oxycodone Hcl | 15 | $195 |
| Azithromycin | 20 | $74 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in New York
- Sheldon FeldmanNew York$97K
- Kepal PatelNew York$94K
- George PlitasNew York$39K
- James ParkNew York$28K
- Michael LoweNew York$20K
- Scott HananNew York$15K
- Marcovalerio MelisNew York$12K
- Kevin SoaresNew York$10K
- Jennifer CracchioloNew York$9K
- Paul SchmidtNew York$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.